Drug discovery and development in idiopathic pulmonary fibrosis: challenges and opportunities.


Journal

Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391

Informations de publication

Date de publication:
12 2020
Historique:
received: 04 02 2020
revised: 25 08 2020
accepted: 17 09 2020
pubmed: 4 10 2020
medline: 7 10 2021
entrez: 3 10 2020
Statut: ppublish

Résumé

The pharmacological and adverse effect profiles of the two approved therapies for IPF make the development of new therapies challenging. Considering the similarity of the characteristics of drug candidates to Standard of Care is important in defining positioning and development strategies for this disease.

Identifiants

pubmed: 33010480
pii: S1359-6446(20)30376-7
doi: 10.1016/j.drudis.2020.09.019
pii:
doi:

Substances chimiques

Drug Combinations 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2277-2283

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Simon Cruwys (S)

TherapeutAix UG, Juttastrasse 18, 52066, Aachen, Germany.

Peter Hein (P)

TherapeutAix UG, Juttastrasse 18, 52066, Aachen, Germany.

Bob Humphries (B)

TherapeutAix UG, Juttastrasse 18, 52066, Aachen, Germany.

Darcey Black (D)

TherapeutAix UG, Juttastrasse 18, 52066, Aachen, Germany. Electronic address: darcey@therapeutaix.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH